Daniela Alferes de Lima Headley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniela Alferes de Lima Headley has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Hollian Richardson
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
6 shared publicationsChandani Hennayake
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
4 shared publications- James Duncan Chalmers
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
3 shared publications Oriol Sibila
3 shared publications- Stefano Aliberti
Department of Biomedical Sciences, Humanitas University, Milan, Italy
3 shared publications Zsofia Eke
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
3 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (5) , 2601162
Sputum and oral microbiota profiles are associated with long COVID severity and phenotype post-hospitalisation: a UK multicentre, prospective cohort study
Background: Acute COVID-19 alters the airway microbiota. Whether these changes persist post-COVID-19 and contribute to long COVID is unknown. We aimed to describe the microbiota by long COVID severity and subtype, and identify links with inflammation. Methods: Adults were prospectively recruited to the longitudinal UK Post-hospitalisation COVID-19 study (PHOSP-COVID). Patients were grouped by previously described “severity clusters” (of ongoing health impairments) and symptom subgroups. Oral and sputum microbiota (at 6 months post-discharge) were characterised through 16S ribosomal RNA gene amplicon sequencing, and microbiota diversity was assessed. Co-occurrence network analysis identified keystone taxa. Associations between keystone taxa and plasma inflammatory proteins were assessed through Spearman's rank correlations. Results: 771 participants had their microbiota assessed. Of participants with oral rinses and “severity cluster” assignment (mean age 57.5 years), 278 out of 722 (38.5%) were women. The “very severe” cluster, in which disease was predominantly pulmonary in nature, was associated with a distinct microbiota profile post-COVID-19. Reduced lung function was associated with a distinct oral microbiota profile. Persistent neurocognitive symptoms were associated with a distinct oral microbiota profile, while gastrointestinal symptoms were associated with a distinct sputum microbiota profile. Microbiota keystone taxa shifted to a higher prevalence of lactic acid bacteria associated with worse health outcomes. Lactic acid bacteria abundance was associated with elevated blood inflammatory proteins. Conclusion: Distinct oral and sputum microbiota profiles were associated with pulmonary function and with neurocognitive and gastrointestinal symptoms in long COVID. Shifts in keystone microbiota taxa linked with inflammation, based on worse health outcomes, suggest a potential role change for lactic acid bacteria, which may be associated with the host immune response.
- 11 October 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (5) , 2601162
Open AccessSputum and oral microbiota profiles are associated with long COVID severity and phenotype post-hospitalisation: a UK multicentre, prospective cohort study
Background: Acute COVID-19 alters the airway microbiota. Whether these changes persist post-COVID-19 and contribute to long COVID is unknown. We aimed to describe the microbiota by long COVID severity and subtype, and identify links with inflammation. Methods: Adults were prospectively recruited to the longitudinal UK Post-hospitalisation COVID-19 study (PHOSP-COVID). Patients were grouped by previously described “severity clusters” (of ongoing health impairments) and symptom subgroups. Oral and sputum microbiota (at 6 months post-discharge) were characterised through 16S ribosomal RNA gene amplicon sequencing, and microbiota diversity was assessed. Co-occurrence network analysis identified keystone taxa. Associations between keystone taxa and plasma inflammatory proteins were assessed through Spearman's rank correlations. Results: 771 participants had their microbiota assessed. Of participants with oral rinses and “severity cluster” assignment (mean age 57.5 years), 278 out of 722 (38.5%) were women. The “very severe” cluster, in which disease was predominantly pulmonary in nature, was associated with a distinct microbiota profile post-COVID-19. Reduced lung function was associated with a distinct oral microbiota profile. Persistent neurocognitive symptoms were associated with a distinct oral microbiota profile, while gastrointestinal symptoms were associated with a distinct sputum microbiota profile. Microbiota keystone taxa shifted to a higher prevalence of lactic acid bacteria associated with worse health outcomes. Lactic acid bacteria abundance was associated with elevated blood inflammatory proteins. Conclusion: Distinct oral and sputum microbiota profiles were associated with pulmonary function and with neurocognitive and gastrointestinal symptoms in long COVID. Shifts in keystone microbiota taxa linked with inflammation, based on worse health outcomes, suggest a potential role change for lactic acid bacteria, which may be associated with the host immune response.
- Open Access
- 19 March 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Assessment of a bacterial quantification assay to detect and monitor Pseudomonas aeruginosa infection in patients with bronchiectasis
Background: Pseudomonas aeruginosa (PA) is the most commonly detected pathogen in bronchiectasis. The clinical standard of care for pathogen detection is culture, which has low sensitivity. Early detection and improved monitoring could be used to enhance eradication and long-term suppressive treatments. Methods: A novel bacterial quantification assay (BQA) targeting ribosomal RNA for the detection of viable PA was developed. The BQA sensitivity and specificity in patient samples was assessed utilising culture (n=57); as well as BioFire pneumonia panel (n=111) and 16S rRNA gene sequencing (n=62). The potential clinical impact of the BQA in clinical settings was explored using two international patient cohorts. Results: The BQA detected PA in 100% of samples where PA was identified by other methods. The BQA quantification was positively correlated with quantitative culture (r=0.42; p<0.001) and BioFire (r=0.68; p<0.001). The BQA identified PA in an additional 23–44% of cases. To evaluate if this increased detection had clinical implications, we tested sputum samples considered to be PA negative by culture in patients who subsequently tested positive for PA. The BQA detected PA in 8/20 patient samples 8–484 days prior to primary detection by culture. In patients considered to have successful PA eradication by culture, the BQA detected PA in 13 samples from 27 patients who went on to relapse. Conclusions: The BQA is a highly sensitive detection and quantification method for PA. The BQA demonstrated improved detection and treatment monitoring compared to culture, identifying patients who went on to either isolate a first PA or relapse.
- 19 March 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Open AccessAssessment of a bacterial quantification assay to detect and monitor Pseudomonas aeruginosa infection in patients with bronchiectasis
Background: Pseudomonas aeruginosa (PA) is the most commonly detected pathogen in bronchiectasis. The clinical standard of care for pathogen detection is culture, which has low sensitivity. Early detection and improved monitoring could be used to enhance eradication and long-term suppressive treatments. Methods: A novel bacterial quantification assay (BQA) targeting ribosomal RNA for the detection of viable PA was developed. The BQA sensitivity and specificity in patient samples was assessed utilising culture (n=57); as well as BioFire pneumonia panel (n=111) and 16S rRNA gene sequencing (n=62). The potential clinical impact of the BQA in clinical settings was explored using two international patient cohorts. Results: The BQA detected PA in 100% of samples where PA was identified by other methods. The BQA quantification was positively correlated with quantitative culture (r=0.42; p<0.001) and BioFire (r=0.68; p<0.001). The BQA identified PA in an additional 23–44% of cases. To evaluate if this increased detection had clinical implications, we tested sputum samples considered to be PA negative by culture in patients who subsequently tested positive for PA. The BQA detected PA in 8/20 patient samples 8–484 days prior to primary detection by culture. In patients considered to have successful PA eradication by culture, the BQA detected PA in 13 samples from 27 patients who went on to relapse. Conclusions: The BQA is a highly sensitive detection and quantification method for PA. The BQA demonstrated improved detection and treatment monitoring compared to culture, identifying patients who went on to either isolate a first PA or relapse.
- Open Access
- 19 March 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Rapid molecular detection of respiratory pathogens in patients with bronchiectasis
Extract Recurrent respiratory infections are a challenging aspect of bronchiectasis management [1, 2]. The most common pathogens detected are Pseudomonas aeruginosa, Haemophilus influenzae, Enterobacteriaceae, Staphylococcus aureus, Streptococcus pneumoniae and Moraxella catarrhalis [1]. Detection of pathogens from patient samples typically rely on culture and DNA based methods [3–5].
- 19 March 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Open AccessRapid molecular detection of respiratory pathogens in patients with bronchiectasis
Extract Recurrent respiratory infections are a challenging aspect of bronchiectasis management [1, 2]. The most common pathogens detected are Pseudomonas aeruginosa, Haemophilus influenzae, Enterobacteriaceae, Staphylococcus aureus, Streptococcus pneumoniae and Moraxella catarrhalis [1]. Detection of pathogens from patient samples typically rely on culture and DNA based methods [3–5].
- 21 August 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2500287
The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC)
Background: The microbiome is associated with exacerbation risk, quality of life and mortality in COPD. Inhaled corticosteroid (ICS) treatment has been reported to alter the microbiome through modulating host defence. How ICS alters the microbiome and whether effects are equal between different ICS preparations is debated. The aim of the MUSIC trial was to investigate whether commonly used ICS therapies have different effects on the airway microbiome in COPD. Methods: This was a multicentre randomised controlled trial. After a 4-week washout period during which they withdrew from ICS, patients with COPD (forced expiratory volume in 1 s versus FS500, with sputum bacterial load the key secondary end-point. Results: 122 participants started the washout period. ICS withdrawal was poorly tolerated; 61 participants withdrew before randomisation with 45 experiencing an exacerbation. 61 patients were randomised. No statistically significant differences were observed for the primary comparison of BF400 versus FS500 in oropharyngeal bacterial load. There was, however, a significant increase in sputum bacterial load with FS500 compared to BF400 by month 3. This difference was not seen with FS250. No significant differences in microbiome α-diversity were observed over time. Adverse events were similar between the groups. Conclusion: FS500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD.
- 21 August 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2500287
The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC)
Background: The microbiome is associated with exacerbation risk, quality of life and mortality in COPD. Inhaled corticosteroid (ICS) treatment has been reported to alter the microbiome through modulating host defence. How ICS alters the microbiome and whether effects are equal between different ICS preparations is debated. The aim of the MUSIC trial was to investigate whether commonly used ICS therapies have different effects on the airway microbiome in COPD. Methods: This was a multicentre randomised controlled trial. After a 4-week washout period during which they withdrew from ICS, patients with COPD (forced expiratory volume in 1 s versus FS500, with sputum bacterial load the key secondary end-point. Results: 122 participants started the washout period. ICS withdrawal was poorly tolerated; 61 participants withdrew before randomisation with 45 experiencing an exacerbation. 61 patients were randomised. No statistically significant differences were observed for the primary comparison of BF400 versus FS500 in oropharyngeal bacterial load. There was, however, a significant increase in sputum bacterial load with FS500 compared to BF400 by month 3. This difference was not seen with FS250. No significant differences in microbiome α-diversity were observed over time. Adverse events were similar between the groups. Conclusion: FS500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD.
- Open Access
- 22 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2500054
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study
Background: The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) registry shows considerable variation in culturable microbes in sputum between different European countries. The additive role of next-generation metagenomic sequencing remains unexplored and the association with antimicrobial resistomes unknown. Methods: We used next-generation shotgun metagenomic sequencing to prospectively assess sputum from 349 individuals recruited into the EMBARC Bronchiectasis Research Involving Databases, Genomics and Endotyping (BRIDGE) study from three European regions: Northern and Western Europe, Southern Europe and the UK. Samples were included from eight European countries. Microbiome and resistome profiles were assessed in relation to clinical outcomes. Results: Next-generation metagenomic sequencing reproduced differences between countries in microbial profiles that were previously shown by culture in the EMBARC study. Metagenomics provided enhanced detection for some bronchiectasis pathogens, including Pseudomonas aeruginosa, Haemophilus influenzae and Streptococcus pneumoniae. Three metagenomic microbial clusters dominated by the genera Pseudomonas, Streptococcus and Haemophilus demonstrated pan-European but variable distribution. Diverse resistomes, linked to underlying microbiomes, were identified across Europe, with significantly higher diversity of resistance gene determinants in Southern Europe. Resistome composition significantly differed between regions, characterised by regionally contrasting multidrug-resistant profiles. The EMBARC-BRIDGE cohort validated established bronchiectasis resistotypes RT1 and RT2, which occur at varying frequency across regions. Despite geographic variation in microbiome and resistome profiles in bronchiectasis across Europe, analogous antimicrobial resistance gene profiles associated with the key bronchiectasis genera Pseudomonas, Streptococcus and Haemophilus, independent of country or region. Conclusion: Sputum metagenomics confirms and extends prior observations of regional variation in bronchiectasis microbiology. Important variation in the distribution of pathogens and antimicrobial resistance genes has implications for antimicrobial practices across Europe.
- 22 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2500054
Open AccessSputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study
Background: The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) registry shows considerable variation in culturable microbes in sputum between different European countries. The additive role of next-generation metagenomic sequencing remains unexplored and the association with antimicrobial resistomes unknown. Methods: We used next-generation shotgun metagenomic sequencing to prospectively assess sputum from 349 individuals recruited into the EMBARC Bronchiectasis Research Involving Databases, Genomics and Endotyping (BRIDGE) study from three European regions: Northern and Western Europe, Southern Europe and the UK. Samples were included from eight European countries. Microbiome and resistome profiles were assessed in relation to clinical outcomes. Results: Next-generation metagenomic sequencing reproduced differences between countries in microbial profiles that were previously shown by culture in the EMBARC study. Metagenomics provided enhanced detection for some bronchiectasis pathogens, including Pseudomonas aeruginosa, Haemophilus influenzae and Streptococcus pneumoniae. Three metagenomic microbial clusters dominated by the genera Pseudomonas, Streptococcus and Haemophilus demonstrated pan-European but variable distribution. Diverse resistomes, linked to underlying microbiomes, were identified across Europe, with significantly higher diversity of resistance gene determinants in Southern Europe. Resistome composition significantly differed between regions, characterised by regionally contrasting multidrug-resistant profiles. The EMBARC-BRIDGE cohort validated established bronchiectasis resistotypes RT1 and RT2, which occur at varying frequency across regions. Despite geographic variation in microbiome and resistome profiles in bronchiectasis across Europe, analogous antimicrobial resistance gene profiles associated with the key bronchiectasis genera Pseudomonas, Streptococcus and Haemophilus, independent of country or region. Conclusion: Sputum metagenomics confirms and extends prior observations of regional variation in bronchiectasis microbiology. Important variation in the distribution of pathogens and antimicrobial resistance genes has implications for antimicrobial practices across Europe.
- Open Access
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Seroprevalence ofBordetella pertussisin patients with COPD in a UK cohort
Exacerbations are key events in the natural history of COPD as they contribute to lung function decline and therefore disease progression [1]. Exacerbations are heterogeneous and it is well-described that exacerbations of COPD may be caused by bacterial infections, viral infections, eosinophilic inflammation, exogenous toxins such as air pollution and worsening of comorbidities [2, 3]. Some causes of exacerbation are preventable with pharmacotherapy and vaccination, but many are not [4]. Therefore, identifying potentially preventable causes of COPD exacerbation is important to reduce the burden of disease [5].
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Open AccessSeroprevalence ofBordetella pertussisin patients with COPD in a UK cohort
Exacerbations are key events in the natural history of COPD as they contribute to lung function decline and therefore disease progression [1]. Exacerbations are heterogeneous and it is well-described that exacerbations of COPD may be caused by bacterial infections, viral infections, eosinophilic inflammation, exogenous toxins such as air pollution and worsening of comorbidities [2, 3]. Some causes of exacerbation are preventable with pharmacotherapy and vaccination, but many are not [4]. Therefore, identifying potentially preventable causes of COPD exacerbation is important to reduce the burden of disease [5].
- Open Access
- 30 April 2020
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 158,p. e60460
A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), a pathogen classified by the United Nations (UN) as a dangerous category B biological substance. For the sake of the workers’ safety, handling of all samples presumed to carry Mtb must be conducted in a containment level (CL) 3 laboratory. The TB molecular bacterial load assay (TB-MBLA) test is a reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) test that quantifies Mtb bacillary load using primers and dual-labelled probes for 16S rRNA. We describe the use of heat inactivation to render TB samples noninfectious while preserving RNA for the TB-MBLA. A 1 mL aliquot of the sputum sample in tightly closed 15 mL centrifuge tubes is boiled for 20 min at either 80 °C, 85 °C, or 95 °C to inactivate Mtb bacilli. Cultivation of the heat inactivated and control (live) samples for 42 days confirmed the death of TB. The inactivated sample is then spiked with 100 µL of the extraction control and RNA is extracted following the standard RNA isolation procedure. No growth was observed in the cultures of heat treated samples. The isolated RNA is subjected to real-time RT-qPCR, which amplifies a specific target in the Mtb 16S rRNA gene, yielding results in the form of quantification cycles (Cq). A standard curve is used to translate Cq into bacterial load, or estimated colony forming units per mL (eCFU/mL). There is an inverse relationship between Cq and the bacterial load of a sample. The limitation is that heat inactivation lyses some cells, exposing the RNA to RNases that cause a loss of 10eCFU/mL (i.e., <10 CFU/mL). Further studies will determine the proportion of very low burden patients that cause false negative results due to heat inactivation.
- 30 April 2020
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 158,p. e60460
Open AccessA Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), a pathogen classified by the United Nations (UN) as a dangerous category B biological substance. For the sake of the workers’ safety, handling of all samples presumed to carry Mtb must be conducted in a containment level (CL) 3 laboratory. The TB molecular bacterial load assay (TB-MBLA) test is a reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) test that quantifies Mtb bacillary load using primers and dual-labelled probes for 16S rRNA. We describe the use of heat inactivation to render TB samples noninfectious while preserving RNA for the TB-MBLA. A 1 mL aliquot of the sputum sample in tightly closed 15 mL centrifuge tubes is boiled for 20 min at either 80 °C, 85 °C, or 95 °C to inactivate Mtb bacilli. Cultivation of the heat inactivated and control (live) samples for 42 days confirmed the death of TB. The inactivated sample is then spiked with 100 µL of the extraction control and RNA is extracted following the standard RNA isolation procedure. No growth was observed in the cultures of heat treated samples. The isolated RNA is subjected to real-time RT-qPCR, which amplifies a specific target in the Mtb 16S rRNA gene, yielding results in the form of quantification cycles (Cq). A standard curve is used to translate Cq into bacterial load, or estimated colony forming units per mL (eCFU/mL). There is an inverse relationship between Cq and the bacterial load of a sample. The limitation is that heat inactivation lyses some cells, exposing the RNA to RNases that cause a loss of 10eCFU/mL (i.e., <10 CFU/mL). Further studies will determine the proportion of very low burden patients that cause false negative results due to heat inactivation.
- Open Access
- 1 December 2017
- Published by Microbiology Society in Microbiology
- Vol. 163 (12) , 1839-1850
Haem-iron plays a key role in the regulation of the Ess/type VII secretion system of Staphylococcus aureus RN6390
The Staphylococcus aureus type VII protein secretion system (T7SS) plays important roles in virulence and intra-species competition. Here we show that the T7SS in strain RN6390 is activated by supplementing the growth medium with haemoglobin, and its cofactor haemin (haem B). Transcript analysis and secretion assays suggest that activation by haemin occurs at a transcriptional and a post-translational level. Loss of T7 secretion activity by deletion of essC results in upregulation of genes required for iron acquisition. Taken together these findings suggest that the T7SS plays a role in iron homeostasis in at least some S. aureus strains.
- 1 December 2017
- Published by Microbiology Society in Microbiology
- Vol. 163 (12) , 1839-1850
Open AccessHaem-iron plays a key role in the regulation of the Ess/type VII secretion system of Staphylococcus aureus RN6390
The Staphylococcus aureus type VII protein secretion system (T7SS) plays important roles in virulence and intra-species competition. Here we show that the T7SS in strain RN6390 is activated by supplementing the growth medium with haemoglobin, and its cofactor haemin (haem B). Transcript analysis and secretion assays suggest that activation by haemin occurs at a transcriptional and a post-translational level. Loss of T7 secretion activity by deletion of essC results in upregulation of genes required for iron acquisition. Taken together these findings suggest that the T7SS plays a role in iron homeostasis in at least some S. aureus strains.